Medical devices, healthcare technology and the business of care
COMPANY INTELLIGENCE

Medtronic Neuromodulation

Explore this company’s associated devices, FDA decisions and regulatory history.

Clinical monitoring equipment, editorial photography

Medtronic Neuromodulation

Regulatory records
130
Linked recall entries
14
Headquarters
Not reported
Brand website
medtronic.com
COMPANY INTELLIGENCE

What the linked records show

MedtechLedger currently links 130 FDA records to the applicant name Medtronic Neuromodulation. It includes 4 original PMA approvals. 28 entries are PMA supplements. 98 entries are 30-day notices. These are records held by this publication, rather than a count of the company’s entire portfolio.

The dated entries run from Nov 30, 1984 to Oct 30, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.

Product code LGW appears in 41 of the 130 linked filings. The collection spans 4 FDA product codes and 4 original PMA application families. These figures describe the filings available here; they do not establish the company’s total device sales or market share.

The largest PMA family in this collection is P840001, with 41 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes. 16 linked filings have a current plain-language explanation checked against the recorded FDA decision.

Applicant mailing address recorded by FDA: 7000 Central Ave., NE, Minneapolis, MN, 55432. Recorded on P840001/S636, decision dated Oct 30, 2026.

Changes described in PMA records

P840001/S636: Restore, Itrel, Synergy, Intellis, Vanta and Inceptiv Spinal Cord Stimulation Systems and Pisces-Quad, Specify,

FDA recorded decision OK30 on October 30, 2026 for Medtronic Neuromodulation's P840001/S636. This 30-Day Notice concerns production changes: an additional surface mount technology (SMT) line, a revised manufacturing sequence, and inspection and de-paneling equipment for printed circuit board assembly production. The database places the entry under process changes involving a manufacturer, sterilizer, packager or supplier.

The statement specifies that automated optical inspection will occur immediately after each SMT assembly stage. It also describes an equivalent solder paste inspection system and a qualified de-paneling machine. These are the particular factory steps and equipment identified in this notice. The record does not supply machine specifications, inspection acceptance limits, validation results or the full production procedure. It identifies product code LGW and the Neurology specialty, but provides no separate clinical findings for these manufacturing changes.

FDA approval-order wording

approval for the following three changes: 1) Adding a new surface mount technology (SMT) production line.2) Revision of the SMT manufacturing process sequence to perform automated optical inspection immediately following each SMT assembly stage.3) Addition of an equivalent solder paste inspection system and addition of a qualified de-paneling machine for PCBA production

Oct 30, 2026 · 30-Day Notice

P970004/S460: InterStim Therapy System, Verify Evaluation System (SNS Urinary Neurostimulator 97800), (SNS Urinary Neurostimulator I

The FDA recorded decision OK30 on 2026-10-29 for PMA supplement P970004/S460, submitted by Medtronic Neuromodulation as a 30-Day Notice for a process change affecting manufacturing, sterilization, packaging or supplier operations. The supplement sits under P970004, whose listed title covers the InterStim Therapy System and Verify Evaluation System, including the SNS Urinary Neurostimulator 97800. The device category is an electrical implantable stimulator for incontinence, with gastroenterology and urology specialties and product code EZW.

The recorded statement describes battery-line process controls rather than a new approval of the whole system: enhanced operator verification of the FactoryWorks step and recorded battery pre-weight, pre- and post-weight out-of-control action plans, software and human machine interface updates that reject batteries above the established final-fill reasonable limit, dedicated white work-in-progress trays, an isopropyl alcohol wipe for residual electrolyte, and removal of Ball Press and Button Press certification prerequisites for ram changes on Medium Rate Line 2, with supervisors and engineers retaining certification responsibility. No documents were provided, so the underlying supplement filing and any clinical or labeling effect remain unknown.

The listed date is in the future relative to typical publication timelines, and the source does not state whether the notice was accepted without further review or what follow-up applies. Whether these manufacturing changes alter device performance or labeling cannot be determined from the record.

FDA approval-order wording

1. Enhanced operator verification of the applicable FactoryWorks processing step and recorded battery pre-weight.2. Addition of pre-weight and post-weight out-of-control action plans to the applicable Process Operation Descriptions.3. Software and Human Machine Interface updates that will automatically reject batteries with fill weights above the established final-fill reasonable limit.4. Introduction of dedicated white work-in-progress trays to distinguish electrolyte-filled batteries and improve line clearance, handling, and traceability.5. Use of an isopropyl alcohol wipe to remove residual electrolyte from battery surfaces before subsequent processing.6. Removal of the Ball Press and Button Press certification prerequisites from the Ball and Button Press Ram Change procedure, allowing Medium Rate Line 2 operators to qualify for press ram changes by completing only the ram-change procedure while supervisors and engineers retain responsibility for operator certification

Oct 29, 2026 · 30-Day Notice

P080025/S354: InterStim Therapy System, Verify Evaluation System (SNS Bowel Neurostimulator 97800), (SNS Bowel Neurostimulators Impl

FDA posted a 30-day notice for supplement S354 to PMA P080025, submitted by Medtronic Neuromodulation for the InterStim Therapy System and Verify Evaluation System. The supplement reason is a process change involving the manufacturer, sterilizer, packager, or supplier. The decision field records OK30, and the product code is QON for an implanted electrical device intended for treatment of fecal incontinence.

The statement lists six manufacturing changes: enhanced operator verification of a FactoryWorks processing step and recorded battery pre-weight; addition of pre-weight and post-weight out-of-control action plans to Process Operation Descriptions; software and human machine interface updates that automatically reject batteries above the final-fill reasonable limit; dedicated white work-in-progress trays for electrolyte-filled batteries; an isopropyl alcohol wipe to remove residual electrolyte; and removal of Ball Press and Button Press certification prerequisites from the ram-change procedure, with supervisors and engineers retaining responsibility for operator certification. The notice does not establish safety or clinical effectiveness.

FDA approval-order wording

1. Enhanced operator verification of the applicable FactoryWorks processing step and recorded battery pre-weight.2. Addition of pre-weight and post-weight out-of-control action plans to the applicable Process Operation Descriptions.3. Software and Human Machine Interface updates that will automatically reject batteries with fill weights above the established final-fill reasonable limit.4. Introduction of dedicated white work-in-progress trays to distinguish electrolyte-filled batteries and improve line clearance, handling, and traceability.5. Use of an isopropyl alcohol wipe to remove residual electrolyte from battery surfaces before subsequent processing.6. Removal of the Ball Press and Button Press certification prerequisites from the Ball and Button Press Ram Change procedure, allowing Medium Rate Line 2 operators to qualify for press ram changes by completing only the ram-change procedure while supervisors and engineers retain responsibility for operator certification

Oct 29, 2026 · 30-Day Notice

P840001/S635: Master Restore, Itrel, Synergy Intellis, Vanta and Inceptiv Spinal Cord Stimulation Systems and Pisces, Specify,

FDA posted a 30-day notice for PMA supplement S635 to P840001, covering Medtronic Neuromodulation spinal cord stimulation systems and leads. The dated statement lists six manufacturing process changes: enhanced operator verification of a FactoryWorks processing step and recorded battery pre-weight; addition of pre-weight and post-weight out-of-control action plans to Process Operation Descriptions; software and human machine interface updates that automatically reject batteries with fill weights above the established final-fill reasonable limit; introduction of dedicated white work-in-progress trays to distinguish electrolyte-filled batteries; use of an isopropyl alcohol wipe to remove residual electrolyte from battery surfaces; and removal of Ball Press and Button Press certification prerequisites from the ram change procedure.

The notice is a process change supplement, not a new approval of the whole system or an original PMA. The statement reports the intended purpose of the changes, such as improving line clearance, handling, and traceability, but does not independently establish safety or clinical effectiveness. No clinical indication, trial data, or benefit assessment is included. The source does not state whether these changes affect device labeling or performance specifications.

FDA approval-order wording

1. Enhanced operator verification of the applicable FactoryWorks processing step and recorded battery pre-weight.2. Addition of pre-weight and post-weight out-of-control action plans to the applicable Process Operation Descriptions.3. Software and Human Machine Interface updates that will automatically reject batteries with fill weights above the established final-fill reasonable limit.4. Introduction of dedicated white work-in-progress trays to distinguish electrolyte-filled batteries and improve line clearance, handling, and traceability.5. Use of an isopropyl alcohol wipe to remove residual electrolyte from battery surfaces before subsequent processing.6. Removal of the Ball Press and Button Press certification prerequisites from the Ball and Button Press Ram Change procedure, allowing Medium Rate Line 2 operators to qualify for press ram changes by completing only the ram-change procedure while supervisors and engineers retain responsibility for operator certification

Oct 29, 2026 · 30-Day Notice

P970004/S459: InterStim Therapy System, Verify Evaluation System

The FDA record P970004/S459, decided 2026-10-09 as OK30 under a 30-Day Notice for a process change involving a manufacturer, sterilizer, packager, or supplier, covers the InterStim Therapy System and Verify Evaluation System. The stated purpose is approval to introduce a second Medium Rate (MR) Header manufacturing line, MR Line 2, and to make inspection updates to the MR Headers Line currently in production at Medtronic Energy and Components Center (MECC), Brooklyn Center, MN. The applicant is Medtronic Neuromodulation; the device category is an electrical implantable stimulator for incontinence, product code EZW.

This is a supplement to PMA P970004, not a new approval of the whole system, and the notice concerns manufacturing and inspection at one site. The record does not describe header specifications, the inspection changes, validation data, or any clinical or safety finding; the stated purpose alone does not establish safety or effectiveness.

FDA approval-order wording

approval for the introduction of a second Medium Rate (MR) Headers manufacturing line (MR Line 2) and to make inspection updates to the MR Headers Line that is currently in production at Medtronic Energy and Components Center (MECC), Brooklyn Center, MN.

Oct 9, 2026 · 30-Day Notice

Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.

RECALL COVERAGE

Recalls linked to this firm

MedtechLedger links 14 FDA enforcement entries through the recorded recalling firm or an exact submission number published in FDA’s recall data. 14 Class II records are represented. Each row is an enforcement entry; one recall event can cover several product entries. These counts describe this collection and do not measure a manufacturer’s safety record or an injury rate.

Recall / productCompanyClassificationReport dateSource
Medtronic NeuromodulationClass IIOct 28, 2026FDA
Medtronic NeuromodulationClass IIOct 28, 2026FDA
Medtronic NeuromodulationClass IIJun 3, 2026FDA
Medtronic NeuromodulationClass IIJun 3, 2026FDA
Medtronic NeuromodulationClass IIMay 20, 2026FDA
Medtronic NeuromodulationClass IIJan 21, 2026FDA

Connections use the recorded recalling firm or the submission identifiers shown below. A shared submission connects the records; it does not establish that differently named legal applicants are interchangeable. Use the exact affected models, lots and instructions on each notice.

Search the firm’s recall records
Source information

Source updated Nov 11, 2026. Retrieved Nov 21, 2026.

Regulatory record history

Product / regulatory recordCompanyPathwayDecision dateSource
Medtronic NeuromodulationPMA supplementOct 30, 2026FDA
Medtronic NeuromodulationPMA supplementOct 29, 2026FDA
Medtronic NeuromodulationPMA supplementOct 29, 2026FDA
Medtronic NeuromodulationPMA supplementOct 29, 2026FDA
Medtronic NeuromodulationPMA supplementOct 9, 2026FDA
Medtronic NeuromodulationPMA supplementOct 9, 2026FDA
Medtronic NeuromodulationPMA supplementOct 6, 2026FDA
Medtronic NeuromodulationPMA supplementOct 6, 2026FDA
Medtronic NeuromodulationPMA supplementOct 6, 2026FDA
Medtronic NeuromodulationPMA supplementSep 24, 2026FDA
Medtronic NeuromodulationPMA supplementSep 14, 2026FDA
Medtronic NeuromodulationPMA supplementSep 14, 2026FDA
AltavivaP240011/S016
Medtronic NeuromodulationPMA supplementSep 14, 2026FDA
Medtronic NeuromodulationPMA supplementAug 21, 2026FDA
Medtronic NeuromodulationPMA supplementAug 14, 2026FDA
Medtronic NeuromodulationPMA supplementAug 14, 2026FDA
AltavivaP240011/S015
Medtronic NeuromodulationPMA supplementAug 14, 2026FDA
Medtronic NeuromodulationPMA supplementAug 14, 2026FDA
Medtronic NeuromodulationPMA supplementAug 8, 2026FDA
Medtronic NeuromodulationPMA supplementAug 8, 2026FDA
AltavivaP240011/S010
Medtronic NeuromodulationPMA supplementJul 13, 2026FDA
Medtronic NeuromodulationPMA supplementJul 1, 2026FDA
Medtronic NeuromodulationPMA supplementJun 16, 2026FDA
AltavivaP240011/S014
Medtronic NeuromodulationPMA supplementJun 16, 2026FDA
Medtronic NeuromodulationPMA supplementJun 16, 2026FDA
Medtronic NeuromodulationPMA supplementJun 16, 2026FDA
Medtronic NeuromodulationPMA supplementJun 12, 2026FDA
Medtronic NeuromodulationPMA supplementJun 12, 2026FDA
Medtronic NeuromodulationPMA supplementJun 5, 2026FDA
Medtronic NeuromodulationPMA supplementJun 5, 2026FDA
Medtronic NeuromodulationPMA supplementJun 5, 2026FDA
Medtronic NeuromodulationPMA supplementJun 4, 2026FDA
Medtronic NeuromodulationPMA supplementJun 4, 2026FDA
Medtronic NeuromodulationPMA supplementMay 22, 2026FDA
Medtronic NeuromodulationPMA supplementMay 22, 2026FDA
Medtronic NeuromodulationPMA supplementMay 22, 2026FDA
Medtronic NeuromodulationPMA supplementMay 22, 2026FDA
Medtronic NeuromodulationPMA supplementMay 20, 2026FDA
AltavivaP240011/S013
Medtronic NeuromodulationPMA supplementMay 13, 2026FDA
Medtronic NeuromodulationPMA supplementMay 13, 2026FDA
Medtronic NeuromodulationPMA supplementMay 7, 2026FDA
Medtronic NeuromodulationPMA supplementMay 7, 2026FDA
Medtronic NeuromodulationPMA supplementMay 7, 2026FDA
Medtronic NeuromodulationPMA supplementMay 1, 2026FDA
Medtronic NeuromodulationPMA supplementMay 1, 2026FDA
AltavivaP240011/S012
Medtronic NeuromodulationPMA supplementApr 3, 2026FDA
Medtronic NeuromodulationPMA supplementApr 3, 2026FDA
Medtronic NeuromodulationPMA supplementApr 3, 2026FDA
Medtronic NeuromodulationPMA supplementApr 3, 2026FDA
AltavivaP240011/S011
Medtronic NeuromodulationPMA supplementMar 26, 2026FDA
Medtronic NeuromodulationPMA supplementMar 18, 2026FDA
Medtronic NeuromodulationPMA supplementMar 18, 2026FDA
AltavivaP240011/S008
Medtronic NeuromodulationPMA supplementFeb 27, 2026FDA
Medtronic NeuromodulationPMA supplementFeb 27, 2026FDA
Medtronic NeuromodulationPMA supplementFeb 27, 2026FDA
Medtronic NeuromodulationPMA supplementFeb 27, 2026FDA
Medtronic NeuromodulationPMA supplementFeb 24, 2026FDA
Medtronic NeuromodulationPMA supplementFeb 24, 2026FDA
Medtronic NeuromodulationPMA supplementFeb 19, 2026FDA
Medtronic NeuromodulationPMA supplementFeb 13, 2026FDA
Medtronic NeuromodulationPMA supplementFeb 12, 2026FDA
Medtronic NeuromodulationPMA supplementFeb 12, 2026FDA
Medtronic NeuromodulationPMA supplementFeb 12, 2026FDA
Medtronic NeuromodulationPMA supplementFeb 12, 2026FDA
Medtronic NeuromodulationPMA supplementFeb 11, 2026FDA
Medtronic NeuromodulationPMA supplementFeb 11, 2026FDA
Medtronic NeuromodulationPMA supplementFeb 11, 2026FDA
Medtronic NeuromodulationPMA supplementFeb 6, 2026FDA
Medtronic NeuromodulationPMA supplementFeb 6, 2026FDA
Medtronic NeuromodulationPMA supplementJan 20, 2026FDA
Medtronic NeuromodulationPMA supplementJan 20, 2026FDA
AltavivaP240011/S005
Medtronic NeuromodulationPMA supplementJan 14, 2026FDA
Medtronic NeuromodulationPMA supplementJan 14, 2026FDA
Medtronic NeuromodulationPMA supplementJan 14, 2026FDA
Medtronic NeuromodulationPMA supplementDec 23, 2025FDA
Medtronic NeuromodulationPMA supplementDec 23, 2025FDA
Medtronic NeuromodulationPMA supplementDec 22, 2025FDA
Medtronic NeuromodulationPMA supplementDec 22, 2025FDA
Medtronic NeuromodulationPMA supplementDec 22, 2025FDA
Medtronic NeuromodulationPMA supplementDec 19, 2025FDA
Medtronic NeuromodulationPMA supplementDec 18, 2025FDA
AltavivaP240011/S003
Medtronic NeuromodulationPMA supplementNov 26, 2025FDA
Medtronic NeuromodulationPMA supplementNov 26, 2025FDA
Medtronic NeuromodulationPMA supplementNov 26, 2025FDA
Medtronic NeuromodulationPMA supplementNov 26, 2025FDA
Medtronic NeuromodulationPMA supplementNov 13, 2025FDA
Medtronic NeuromodulationPMA supplementNov 4, 2025FDA
Medtronic NeuromodulationPMA supplementNov 4, 2025FDA
Medtronic NeuromodulationPMA supplementNov 4, 2025FDA
Medtronic NeuromodulationPMA supplementOct 23, 2025FDA
Medtronic NeuromodulationPMA supplementOct 21, 2025FDA
Medtronic NeuromodulationPMA supplementOct 17, 2025FDA
Medtronic NeuromodulationPMA supplementOct 16, 2025FDA
Medtronic NeuromodulationPMA supplementOct 16, 2025FDA
Medtronic NeuromodulationPMA supplementOct 16, 2025FDA
Medtronic NeuromodulationPMA approvalSep 18, 2025FDA
Medtronic NeuromodulationPMA supplementSep 18, 2025FDA
Medtronic NeuromodulationPMA supplementSep 18, 2025FDA
Medtronic NeuromodulationPMA supplementSep 18, 2025FDA
Medtronic NeuromodulationPMA supplementSep 15, 2025FDA
Medtronic NeuromodulationPMA supplementSep 15, 2025FDA
Medtronic NeuromodulationPMA supplementSep 15, 2025FDA
Medtronic NeuromodulationPMA supplementSep 10, 2025FDA
Medtronic NeuromodulationPMA supplementSep 10, 2025FDA
Medtronic NeuromodulationPMA supplementSep 5, 2025FDA
Medtronic NeuromodulationPMA supplementSep 5, 2025FDA
Medtronic NeuromodulationPMA supplementSep 5, 2025FDA
Medtronic NeuromodulationPMA supplementAug 28, 2025FDA
Medtronic NeuromodulationPMA supplementAug 28, 2025FDA
Medtronic NeuromodulationPMA supplementAug 28, 2025FDA
Medtronic NeuromodulationPMA supplementAug 14, 2025FDA
Medtronic NeuromodulationPMA supplementAug 6, 2025FDA
Medtronic NeuromodulationPMA supplementAug 6, 2025FDA
Medtronic NeuromodulationPMA supplementAug 6, 2025FDA
Medtronic NeuromodulationPMA supplementAug 1, 2025FDA
Medtronic NeuromodulationPMA supplementAug 1, 2025FDA
Medtronic NeuromodulationPMA supplementJul 29, 2025FDA
Medtronic NeuromodulationPMA supplementJul 28, 2025FDA
Medtronic NeuromodulationPMA supplementJul 28, 2025FDA
Medtronic NeuromodulationPMA supplementJul 22, 2025FDA
Medtronic NeuromodulationPMA supplementJul 17, 2025FDA
Medtronic NeuromodulationPMA supplementJul 17, 2025FDA
Medtronic NeuromodulationPMA supplementJul 17, 2025FDA
Medtronic NeuromodulationPMA supplementJul 17, 2025FDA
Medtronic NeuromodulationPMA supplementJul 17, 2025FDA
Medtronic NeuromodulationPMA supplementJul 17, 2025FDA
Medtronic NeuromodulationPMA supplementJul 16, 2025FDA
Medtronic NeuromodulationPMA approvalMar 14, 2011FDA
Medtronic NeuromodulationPMA approvalSep 29, 1997FDA
Medtronic NeuromodulationPMA approvalNov 30, 1984FDA
Source information

Source updated Nov 9, 2026. Retrieved Nov 21, 2026.